Akanda Corp (AKAN)vsTeva Pharma Industries Ltd ADR (TEVA)
AKAN
Akanda Corp
$0.79
-1.45%
HEALTHCARE · Cap: $1.63M
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2062626% more annual revenue ($17.26B vs $836,660). TEVA leads profitability with a 8.2% profit margin vs -2.7%. AKAN trades at a lower P/E of 0.0x. TEVA earns a higher WallStSmart Score of 73/100 (B).
AKAN
Hold36
out of 100
Grade: F
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+99.9%
Fair Value
$1052.91
Current Price
$0.79
$1052.12 discount
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 21.9% year-over-year
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -60.9% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AKAN
The strongest argument for AKAN centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 21.9% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : AKAN
The primary concerns for AKAN are EPS Growth, Market Cap, Return on Equity.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
AKAN profiles as a growth stock while TEVA is a value play — different risk/reward profiles.
AKAN carries more volatility with a beta of 1.69 — expect wider price swings.
AKAN is growing revenue faster at 21.9% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 36/100) and 11.4% revenue growth. AKAN offers better value entry with a 99.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akanda Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akanda Corporation. The company is headquartered in New Romney, the United Kingdom.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?